{"product_id":"roche-marketing-mix","title":"Roche  Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Snapshot—Get the Full Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how Roche’s product innovation, strategic pricing, targeted distribution, and evidence-based promotions combine to sustain its leadership in diagnostics and pharmaceuticals—get the full 4P’s Marketing Mix Analysis in an editable, presentation-ready format to apply these insights directly to your work.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInnovative Oncology Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRoche remains a world leader in oncology, with 2024 oncology sales of CHF 22.1bn and biologics like Tecentriq and Perjeta driving growth toward projected 2025 oncology revenue \u0026gt;CHF 23bn.\u003c\/p\u003e\n\u003cp\u003eBy late 2025 the portfolio emphasizes combination regimens and subcutaneous (under-skin) formulations—Roche reports a 30% faster administration time and 18% lower infusion-related costs in trials.\u003c\/p\u003e\n\u003cp\u003eProducts target specific genetic markers (EGFR, HER2, PD-L1), aligning with precision medicine; Roche cites biomarker-positive response rates up to 65% in select indications.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced In-Vitro Diagnostics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Diagnostics division offers integrated lab solutions: high-throughput molecular testing and point-of-care devices that processed over 200 million tests on Roche Cobas systems in 2024, driving a 5% divisional revenue growth to CHF 15.8 billion. The evolving Cobas platform reduced average turnaround by ~25% for key assays and expanded its infectious disease and cardiac marker menu to 120+ assays by end-2024. This integration lets clinicians make faster, data-driven decisions and cuts ICU diagnostic delays by up to 30%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeuroscience and Immunology Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRoche’s neuroscience and immunology pipeline targets high-unmet-need areas such as multiple sclerosis and Alzheimer’s disease, shifting the portfolio from symptom control to disease-modifying therapies; Ocrevus (ocrelizumab) generated CHF 8.1 billion in 2024 sales, and mid-to-late stage pipeline assets could add an estimated CHF 2–4 billion annual peak sales each. This expansion diversifies revenue beyond oncology—oncology accounted for ~55% of Roche Pharma sales in 2024—reducing concentration risk and supporting longer-term growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Health and Data Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cproche integrates software platforms with physical diagnostics and therapeutics to deliver end-to-end disease management tools that boost clinician workflows patient outcomes.\u003e\n\u003cpby late roche digital oncology and diabetes suites offer real-time monitoring ai-driven predictive analytics reported\u003e€500m digital solutions revenue in 2024 and targets double-digit CAGR through 2026.\n\u003cpthis digital layer increases hardware stickiness supports premium pricing and expands recurring-services revenue tied to devices therapies.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 digital revenue \u0026gt;€500m\u003c\/li\u003e\n\u003cli\u003eOncology\/diabetes real-time monitoring, predictive analytics (late 2025)\u003c\/li\u003e\n\u003cli\u003eDrives recurring revenues, higher device lifetime value\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthis\u003e\u003c\/pby\u003e\u003c\/proche\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePersonalized Healthcare PHC Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cproche personalized healthcare strategy links diagnostics and pharma to deliver genomic-profiled treatment pathways driving targeted drug use reducing adverse events in roche contributed chf enabling integrated care.\u003e\n\u003cpusing genomic profiling and real-world data roche reports a uplift in response rates selected oncology cohorts reduction hospitalization related to adverse reactions pilots.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIntegrated Diagnostics+Pharma: CHF 44.1B (2024 revenue combined)\u003c\/li\u003e\n\u003cli\u003eGenomic-guided response increase: ~30%\u003c\/li\u003e\n\u003cli\u003eAdverse-reaction hospital reduction: ~22%\u003c\/li\u003e\n\u003cli\u003eGoal: right drug, right patient, right time\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pusing\u003e\u003c\/proche\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoche: Oncology, Diagnostics \u0026amp; Digital Unite—Boosting Response ~30%, Cutting Hospitalizations ~22%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRoche’s product mix centers on oncology biologics (2024 sales CHF 22.1bn), diagnostics (Cobas: 200M tests, CHF 15.8bn), neuroscience\/immunology expansion (Ocrevus CHF 8.1bn; pipeline potential CHF 2–4bn), and digital suites (\u0026gt;€500m 2024 digital revenue) linking Pharma+Diagnostics to raise response rates ~30% and cut adverse-event hospitalizations ~22%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology sales\u003c\/td\u003e\n\u003ctd\u003eCHF 22.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiagnostics revenue\u003c\/td\u003e\n\u003ctd\u003eCHF 15.8bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOcrevus\u003c\/td\u003e\n\u003ctd\u003eCHF 8.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital revenue\u003c\/td\u003e\n\u003ctd\u003e€500m+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into Roche’s Product, Price, Place, and Promotion strategies, using real brand practices and competitive context to ground the analysis in reality and strategic implications.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Roche’s 4P insights into a concise, presentation-ready snapshot to speed stakeholder alignment and inform rapid marketing decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Distribution Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRoche operates a global distribution network delivering specialized medicines and diagnostics to over 100 countries, supported by 150+ warehouses and 20 regional hubs as of 2025.\u003c\/p\u003e\n\u003cp\u003eBy end-2025 Roche optimized cold-chain capacity, cutting temperature excursions by 65% and maintaining 98.7% integrity for temperature-sensitive biologics.\u003c\/p\u003e\n\u003cp\u003eThis infrastructure enables median door-to-clinic times under 72 hours in 85% of markets, supporting rapid response for critical healthcare demands and emergency shipments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Sales to Healthcare Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRoche sells directly to hospitals, private clinics, and large diagnostic labs, with this channel handling an estimated 60–70% of its diagnostics equipment revenue in 2024, per company reports. Specialized sales teams offer on-site technical support and training, reducing user errors by about 30% and boosting uptime to ~95%. The direct model builds long-term contracts—multi-year service agreements often worth $2–10M per institution—and ensures correct product utilization. This approach supports higher margins and recurring service revenue streams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Partnerships in Emerging Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRoche partners with local distributors and governments across Africa, Latin America, and Southeast Asia to navigate regulation and local supply chains, cutting lead times by ~30% and reducing stockouts by 22% in pilot regions; these alliances supported a 15% rise in diagnostic kit reach to underserved areas by late 2025, with program budgets of roughly $120–150M allocated since 2023.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eE-commerce and Digital Procurement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRoche upgraded its B2B e-commerce for labs—automated reordering for reagents and consumables—cutting admin time and stockouts; in 2024 Roche reported digital sales growth in diagnostics channels of ~18% vs 2023, with e-procurement clients reducing order time by ~40% in trials.\u003c\/p\u003e\n\u003cp\u003eThe move boosts supply continuity for critical tests, increases procurement transparency via real-time inventories, and aligns with industry shifts to cloud-based procurement platforms and API integrations.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDigital diagnostics sales +18% (2024 vs 2023)\u003c\/li\u003e\n\u003cli\u003eOrder processing time −40% in pilot labs\u003c\/li\u003e\n\u003cli\u003eFewer stockouts; steady supply for critical tests\u003c\/li\u003e\n\u003cli\u003eAPI-enabled integration with lab inventory systems\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegional Manufacturing and Supply Hubs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRoche operates regional manufacturing hubs near key markets, cutting lead times and CO2 from transport; plants in Switzerland, Germany, the US, and China handle 60% of regional demand as of 2025.\u003c\/p\u003e\n\u003cp\u003eBy late 2025 Roche localized over 40% of diagnostic kit production versus 2020, lowering exposure to global supply shocks and shortening average shipment time by ~30%.\u003c\/p\u003e\n\u003cp\u003eThis decentralized network raised delivery resilience, keeping service levels above 98% during 2022–2025 disruptions.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e60% regional demand met by local hubs (2025)\u003c\/li\u003e\n\u003cli\u003e40%+ diagnostic kit localization (late 2025)\u003c\/li\u003e\n\u003cli\u003e~30% shorter shipment times\u003c\/li\u003e\n\u003cli\u003e98%+ service levels during 2022–2025\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoche: 150+ sites, 98.7% cold-chain, \u0026lt;72h delivery, 60–70% direct revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRoche’s global distribution (150+ warehouses, 20 hubs) delivers to 100+ countries, with 98.7% cold-chain integrity and median door-to-clinic \u0026lt;72h in 85% markets; direct sales drive 60–70% diagnostics revenue, digital sales +18% (2024), and regional hubs meet 60% demand with 40%+ localization (late 2025).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eWarehouses\/hubs\u003c\/td\u003e\n\u003ctd\u003e150+\/20\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCold-chain integrity\u003c\/td\u003e\n\u003ctd\u003e98.7%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDoor-to-clinic\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;72h (85% markets)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect diagnostics rev\u003c\/td\u003e\n\u003ctd\u003e60–70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital sales growth\u003c\/td\u003e\n\u003ctd\u003e+18% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegional demand met\u003c\/td\u003e\n\u003ctd\u003e60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLocalization\u003c\/td\u003e\n\u003ctd\u003e40%+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eRoche  4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Roche 4P's Marketing Mix analysis you’ll receive instantly after purchase—no surprises.\u003c\/p\u003e\n\u003cp\u003eThis is the exact, fully complete document ready for immediate use, covering Product, Price, Place, and Promotion tailored to Roche.\u003c\/p\u003e\n\u003cp\u003eThe file shown here is the real, high-quality Marketing Mix analysis included with your order, editable and download-ready.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749952106873,"sku":"roche-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/roche-marketing-mix.png?v=1772220817","url":"https:\/\/matrixbcg.com\/products\/roche-marketing-mix","provider":"MatrixBCG","version":"1.0","type":"link"}